Trial · NCT07899918
Dual-Energy Lattice-Tip Assisted Marshall-Plan Strategy in Redo Persistent Atrial Fibrillation Ablation
NCT07899918, Not applicable, Not yet recruiting, Karolinska University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dual-Energy Lattice-Tip Assisted Marshall-Plan Strategy in Redo Persistent Atrial Fibrillation Ablation. Trials, record NCT07899918. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07899918
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dual-Energy Lattice-Tip Assisted Marshall-Plan Strategy in Redo Persistent Atrial Fibrillation Ablation
- NCT number
- NCT07899918
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 234 participants, estimated
- Lead sponsor
- Karolinska University Hospital
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- Marshall Plan-Based Ablation Strategy, PV re-isolation only, Additional Left Atrial Ablation
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Between-group difference in atrial-arrhythmia burden | From the end of the 8-week blanking period through 12 months and before any crossover ablation | Between-group difference in atrial-arrhythmia burden, defined as the percentage of analyzable ILR time spent in atrial arrhythmia, measured during off-AAD intervals from the end of the 8-week blanking period through 12 months and before any crossover ablation, comparing PV re-isolation plus Marshall-plan strategy versus PV re-isolation alone. |
| Secondary | Number of Participants with Freedom from Atrial Arrhythmia after 1 Ablation Procedure without Antiarrhythmic Drugs (AAD) | From the end of the 8-week blanking period through 12 months and before any crossover ablation | 1\. Freedom from AF/AT/AFL ≥30 s at 12 months (after 8-week blanking period), centrally adjudicated |
| Secondary | Arrhythmia burden during off-AAD follow-up time and before any crossover ablation | From the end of the 8-week blanking period through 12 months and before any crossover ablation | Arrhythmia burden during off-AAD follow-up time and before any crossover ablation, with additional sensitivity analyses accounting for DC cardioversion and repeat ablation. |
| Secondary | Arrhythmia burden between groups in patients on AAD | From the end of the 8-week blanking period through 12 months and before any crossover ablation | |
| Secondary | Between-group difference in atrial-arrhythmia burden, percent of analyzable time in AF/AT/AFL by ILR measured irrespective of the AAD use | From the end of the blanking period (week 8) through 12 months, comparing PV re-isolation + Marshall-plan vs PV re-isolation only. | |
| Secondary | Differences in arrhythmia burden without blanking period. | Through 12 months, comparing PV re-isolation + Marshall-plan vs PV re-isolation only. | |
| Secondary | Total procedure time | During the index procedure | |
| Secondary | Total fluoroscopy time | During the index procedure | |
| Secondary | Freedom from DC cardioverted atrial arrhythmia | At 6 and 12 months | |
| Secondary | Freedom from atrial fibrillation | At 6 and 12 months |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers11
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07899918
GET https://conductscience.org/api/trials/v1/NCT07899918/registered